ACS
CRL icon

Archford Capital Strategies’s Charles River Laboratories CRL Stock Holding History

Archford Capital Strategies’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-48
Closed -$7K – 279
2019
Q2 		$7K Hold
48
– – ﹤0.01% 429
2019
Q1 		$7K Hold
48
– – ﹤0.01% 406
2018
Q4 		$5K Hold
48
– – ﹤0.01% 401
2018
Q3 		$6K Hold
48
– – ﹤0.01% 430
2018
Q2 		$5K Hold
48
– – ﹤0.01% 464
2018
Q1 		$5K Buy
+48
New +$5.17K ﹤0.01% 381
2017
Q2 		– Sell
-48
Closed -$4K – 283
2017
Q1 		$4K Buy
+48
New +$4.08K ﹤0.01% 490

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Archford Capital Strategies's CRL Position: Q3 2019 in Review

Archford Capital Strategies sold out of Charles River Laboratories (CRL) in Q3 2019, closing a stake of 48 shares — an estimated $7K sold.

Archford Capital Strategies first reported a position in CRL in Q1 2017 and held it in 7 quarters. The position peaked at $7K in Q2 2019. 396 funds tracked by Wall St. Rank hold CRL as of Q3 2019.

  • Archford Capital Strategies reported no remaining Charles River Laboratories position as of Q3 2019 after selling out during the quarter.
  • Archford Capital Strategies sold 48 Charles River Laboratories shares in Q3 2019, an estimated $7K.
  • Archford Capital Strategies first reported a position in Charles River Laboratories in Q1 2017 and held it in 7 quarters.
  • Archford Capital Strategies's Charles River Laboratories position peaked at $7K in Q2 2019.
  • 396 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2019.

Based on Archford Capital Strategies's 13F filing for Q3 2019, filed 23 Oct 2019.